GRACEcast Lung Cancer Audio

Follow GRACEcast Lung Cancer Audio
Share on
Copy link to clipboard

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

cancerGRACE - H. Jack West, MD


    • Dec 20, 2013 LATEST EPISODE
    • infrequent NEW EPISODES
    • 15m AVG DURATION
    • 136 EPISODES


    More podcasts from cancerGRACE - H. Jack West, MD

    Search for episodes from GRACEcast Lung Cancer Audio with a specific topic:

    Latest episodes from GRACEcast Lung Cancer Audio

    Squamous Lung Cancer Part 5, Q and A Session (audio)

    Play Episode Listen Later Dec 20, 2013 13:58


    Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.

    Squamous Lung Cancer, Part 4: Immunotherapy (audio)

    Play Episode Listen Later Dec 10, 2013 7:06


    Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

    Squamous Lung Cancer, Part 3: Treatment (audio)

    Play Episode Listen Later Dec 8, 2013 12:54


    Squamous Lung Cancer, Part 2: Genomic Testing (audio)

    Play Episode Listen Later Dec 6, 2013 11:34


    Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.

    Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio)

    Play Episode Listen Later Dec 2, 2013 15:09


    Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.

    ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)

    Play Episode Listen Later Sep 4, 2013 5:27


    Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.

    ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)

    Play Episode Listen Later Aug 30, 2013 5:41


    Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

    ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)

    Play Episode Listen Later Aug 26, 2013 5:21


    Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.

    ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)

    Play Episode Listen Later Aug 26, 2013 5:45


    Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

    ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)

    Play Episode Listen Later Aug 23, 2013 9:49


    Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

    ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)

    Play Episode Listen Later Aug 23, 2013 7:17


    Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.

    ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)

    Play Episode Listen Later Aug 16, 2013 4:08


    Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

    ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)

    Play Episode Listen Later Aug 16, 2013 6:38


    Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.

    ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio)

    Play Episode Listen Later Aug 15, 2013 12:58


    Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.

    ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio)

    Play Episode Listen Later Aug 13, 2013 6:19


    Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.

    ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)

    Play Episode Listen Later Aug 12, 2013 8:40


    Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

    ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (audio)

    Play Episode Listen Later Aug 10, 2013 8:45


    Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.

    ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (audio)

    Play Episode Listen Later Aug 7, 2013 7:44


    Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.

    Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)

    Play Episode Listen Later Jun 9, 2013 21:32


    Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.

    Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (audio)

    Play Episode Listen Later May 30, 2013 16:38


    Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.

    Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (audio)

    Play Episode Listen Later May 20, 2013 19:29


    Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.

    Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)

    Play Episode Listen Later May 16, 2013 11:35


    Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

    Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (audio)

    Play Episode Listen Later May 13, 2013 12:38


    Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).

    Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)

    Play Episode Listen Later Apr 6, 2013 3:43


    Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.

    Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (audio)

    Play Episode Listen Later Mar 29, 2013 8:06


    Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

    Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)

    Play Episode Listen Later Mar 29, 2013 5:27


    Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

    Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)

    Play Episode Listen Later Mar 22, 2013 10:37


    Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

    Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)

    Play Episode Listen Later Mar 18, 2013 18:52


    Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

    Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (audio)

    Play Episode Listen Later Mar 12, 2013 10:22


    Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.

    Dr. Harpole on Lung Surgery: Advances in Lung Cancer Staging (audio)

    Play Episode Listen Later Feb 11, 2013 11:13


    Dr. David Harpole of Duke University reviews advances in lung cancer surgery, focusing in this first part on the evolution of techniques to improve staging of lung cancer.

    Managing Pulmonary Complications of Lung Cancer Treatment: Targeted Therapy and Radiation-Induced Lung Damage (audio)

    Play Episode Listen Later Oct 24, 2012 14:19


    Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by EGFR inhibitors or chest radiation.

    Managing Pulmonary Complications of Lung Cancer Treatment: Chemo-Induced Lung Damage (Audio)

    Play Episode Listen Later Oct 14, 2012 17:24


    Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.

    ASCO 2012 Lung Cancer Highlights: Question and Answer Session (audio)

    Play Episode Listen Later Sep 29, 2012 20:33


    Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.

    ASCO 2012 LC Highlights: Dr. Joel Neal on Molecular Targets in Squamous NSCLC (audio)

    Play Episode Listen Later Sep 21, 2012 4:29


    Dr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.

    ASCO 2012 LC Highlights: Dr. Joel Neal on the SELECT Trial of Tarceva (Erlotinib) As Adjuvant Therapy for EGFR Mutation-Positive Advanced NSCLC (audio)

    Play Episode Listen Later Sep 16, 2012 4:51


    Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer. 

    ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)

    Play Episode Listen Later Sep 12, 2012 5:13


    Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.

    ASCO 2012 LC Highlights: Dr. Joel Neal on the MEK Inhibitor Selumetinib in KRAS Mutation-Positive NSCLC (audio)

    Play Episode Listen Later Sep 10, 2012 5:10


    Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).

    ASCO 2012 LC Highlights: Dr. Joel Neal on Anti-PD-1 Immunotherapy for Advanced NSCLC (audio)

    Play Episode Listen Later Sep 4, 2012 7:40


    Dr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).

    ASCO 2012 LC Highlights: Dr. Mark Socinski on Key Trials in Small Cell Lung Cancer (audio)

    Play Episode Listen Later Aug 29, 2012 8:06


    Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.

    ASCO 2012 LC Highlights: Dr. Mark Socinski on TAILOR Trial in EGFR wild type Advanced NSCLC (audio)

    Play Episode Listen Later Aug 26, 2012 7:08


    Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.

    ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (audio)

    Play Episode Listen Later Aug 19, 2012 6:50


    Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

    ASCO 2012 Lung Cancer Highlights: Dr. Mark Socinski on PARAMOUNT Continuation Maintenance Therapy Trial (audio)

    Play Episode Listen Later Aug 16, 2012 8:37


    Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.

    Claim GRACEcast Lung Cancer Audio

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel